Health Care Supplies

MiniMed

MiniMed Released FY2025 Q4 Earnings on June 3, 2026 (EST) with Revenue of $724M and EPS of -$0.6803

MiniMed 于 2026 年 6 月 3 日盘前 (美东时间) 发布 FY2026 Q4 财报，实际营收 837 M USD (预期 826.88 M USD)，实际 EPS -0.6825 USD (预期 -0.3025 USD)

MiniMed 于 2026 年 6 月 3 日盘前 (美东时间) 发布 FY2026 年度财报，实际营收 31.02 亿 USD (预期 30.87 亿 USD)，实际 EPS -1.29 USD (预期 -0.14 USD)

MiniMed to Release FY2026 Q4 Earnings on June 3, Pre-Market EST; Forecast Revenue USD 826.56 M, EPS USD -0.3025

MiniMed Group stock price hits 52-week low

MiniMed released FY2025 Q3 earnings on April 17 (EST), actual revenue USD 687 M, actual EPS USD -0.0395

MiniMed released FY2026 Q3 earnings on April 17 (EST), actual revenue USD 790 M (forecast USD 788.65 M), actual EPS USD -0.4707 (forecast USD 0.1298)

MiniMed released FY2025 9 Months earnings on April 17 (EST), actual revenue USD 1.991 B, actual EPS USD -0.0395

MiniMed released FY2026 9 Months earnings on April 17 (EST), actual revenue USD 2.265 B, actual EPS USD -0.4707

MiniMed Group, Inc. Obtains Abbott CE Certification

MiniMed released FY2026 Semi-Annual earnings on December 19, 2025 (EST), with actual revenue of USD 1.475 B and EPS of USD 0

MMED.US released FY2025 Semi-Annual Earnings on December 19, 2025 (BJT), with actual revenue of USD 1.304 B and EPS of USD 0

MMED.US released FY2026 Q1 earnings on December 19, 2025 (BJT), with actual revenue of USD 737.5 M and EPS of USD 0

MMED.US released FY2025 Q1 earnings on December 19, 2025 (BJT) with actual revenue of USD 652 M and EPS of USD 0

MMED.US released FY2025 Q2 earnings on December 19, 2025 (BJT) with actual revenue of USD 652M and EPS of USD 0

MMED.US released FY2026 Q2 earnings on December 19, 2025 (BJT) with actual revenue of USD 737.5 M and EPS of USD 0

MiniMed released FY2024 Annual Earnings on October 28 (EST), Actual Revenue: USD 2.469 B, Actual EPS: USD 0

MiniMed released FY2025 Annual Earnings on October 28 (EST), actual revenue USD 2.715 B, actual EPS USD 0

MMED.US released FY2023 Annual Earnings on May 30, 2025 (BJT) with actual revenue of USD 2.245 B and EPS of USD 0

Freecast

Cuprina

U-BX Tech

HORIZON SPACE ACQUISITION II CORP COM USD0.0001 30/03/2026(SUB/RIGHTS)

Defiance Pure Space Dly 2X Strat ETF

VS MEDIA

Everbright Digital

Park Ha Biological Tech

Friedman Industries

Defiance Daily Target 2X Short ASTS ETF

MMED

Medtronic (MDT) is poised for a rebound after overselling, with analysts projecting 20-25% upside. Strong Q4 results showed revenue growth of 9.9%, beating expectations, while the company maintains its Dividend King status with a 3.5% yield. Institutional confidence remains high, and the upcoming MiniMed spin-off aims to enhance margins. Despite macro headwinds and cybersecurity risks, Medtronic's valuation at 13x earnings and robust cash flow support a bullish outlook.

Market Beat

Medtronic

S&P 500

SPDR S&P 500

Medtronic Bottoms, Healthy Rebound Ahead

ABVX

CING

DRTS

Top biotech gainers included ABVX (+24.3%), driven by positive Phase 3 ulcerative colitis trial results for Obefazimod; CING (+21.1%), rising on plans to resubmit an NDA for ADHD therapy after FDA cited manufacturing issues; DRTS (+18.5%), surging following a strategic partnership with Tolmar for Alpha DaRT prostate cancer therapy; and MMED (+15.9%), jumping on strong fiscal year financial results.

rttnews

Abivax SA

Cingulate

Alpha Tau Medical

Rezolute

CINGULATE INC C/WTS 10/12/2026 (TO PUR COM)

ALPHA TAU MEDICAL LTD C/WTS (TO PUR COM)

Top Biotech Gainers: ABVX, CING, DRTS, MMED...

PIII

SNGX

ATPC

NOTV

NOTVQ

During Wednesday's intraday session, several healthcare stocks experienced significant volatility. Top gainers included Agape ATP (+41.9%), Abivax (+18.78%), and Minimed Group (+16.3%). Conversely, major losers featured Inotiv (-57.3%), Soligenix (-33.7%), and P3 Health Partners (-19.47%). The report highlights specific price movements and market capitalizations for these companies amid regular trading hours.

benzinga_article

P3 Health Partners

Soligenix

Agape ATP

Inotiv

INOTIV INC

Picard Medical

Liminatus Pharma

Ardent Health

Mineralys Therapeutics

P3 HEALTH PARTNERS INC C/WTS 19/11/2026 (TO PUR COM)

LIMINATUS PHARMA INC C/WTS 30/04/2030 (TO PUR COM)

12 Health Care Stocks Moving In Wednesday's Intraday Session

RLMD

SVCO

U.S. stock futures surged over 7% on Wednesday, driven by AI optimism. Marvell Technology shares jumped 11.73% to $324.92 in pre-market trading after NVIDIA CEO Jensen Huang endorsed the company and highlighted a strategic partnership for next-gen AI data center switches. Other notable gainers included Relmada Therapeutics (+15.41%), Eightco Holdings (+13.27%), Abivax (+13.10%), GameStop (+12.61% following strong Q1 earnings and buyback news), Nextav (+12.21%), Rezolute (+11.74%), Silvaco (+10.92%), BitVentures (+10.85%), and AngioDynamics (+9.19%).

- U.S. stock futures saw significant gains, particularly with Nasdaq futures rising over 7.09%, driven by optimism in the artificial intelligence and enterprise hardware sectors.  
- Marvell Technology Inc. shares surged 11.73% to $324.92 after receiving an endorsement from NVIDIA CEO Jensen Huang, following a 32% rally from the previous session.  
- Other notable pre-market movers included Relmada Therapeutics gaining 15.41%, GameStop rising 12.61%, and AngioDynamics up 9.19%, reflecting broad investor interest across multiple sectors.

Relmada Therapeutics

Silvaco

Eightco

NVIDIA

GameStop

Angiodynamics

Marvell Tech

BitVentures

T-Rex 2X Long NVIDIA Daily Target ETF

SPDR S&P Semicon

Direxion Daily NVDA Bear 1X ETF

Invesco PHLX Semiconductor ETF

Spdr Select Tech

VanEck Semiconductor ETF

AXS 1.5X NVDA Bear Daily ETF

Invesco Semiconductors ETF

GraniteShares 2x Short NVDA Daily ETF

First Trust Nasdaq Food & Semicon

ISHRS S&P Glb It

iShares Semiconductor ETF

T-Rex 2X Long GME Daily Target ETF

Direxion Daily NVDA Bull 2X Shares

Direxion Semicon Bull 3X

YieldMax NVDA Option Income Strategy ETF

GraniteShares 2x Long MRVL Daily ETF

T-Rex 2X Inverse NVIDIA Daily Target ETF

GraniteShares 2x Long NVDA Daily ETF

XL2CSOPNVDA

eBay

NextNav

NVIDIA Corporation

GAMESTOP CORPORATION C/WTS (TO PUR COM) 30/10/2026

NextNav - CW27

Marvell Technology Soars on NVIDIA CEO's Endorsement, Joins Relmada Therapeutics and Other Big Stocks Moving Higher in Wednesday's Pre-Market Session

MiniMed shares rose 7% to $13.14 in pre-market trading after reporting Q4 revenue of $837 million, beating expectations. Growth was driven by a 22% increase in international sales. Additionally, MiniMed expanded its partnership with Abbott Laboratories to commercialize glucose-ketone sensors for its smart dosing systems.

MorningStar

Abbott Laboratories

Factset Research

MiniMed Shares Rise on 4Q Sales, Abbott Partnership Expansion

Minimed Group (NASDAQ:MMED) reported record fiscal 2026 revenue surpassing $3 billion, with Q4 growth of 8.7%. The company launched new products like MiniMed Flex and Go, aiming for ~10% organic revenue growth in fiscal 2027 driven by upcoming launches such as the MiniMed Fit patch pump and Vivera algorithm.

Full Transcript: Minimed Group Q4 2026 Earnings Call